Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Consensus Rating of “Buy” by Analysts

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seventeen ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have given a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $34.4167.

A number of research firms have recently issued reports on MPLT. Stifel Nicolaus lifted their price objective on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Wall Street Zen downgraded shares of Maplight Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Needham & Company LLC raised their price target on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday, July 10th. Canaccord Genuity Group dropped their price target on shares of Maplight Therapeutics from $43.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Finally, Wolfe Research reiterated an “outperform” rating and issued a $30.00 price objective on shares of Maplight Therapeutics in a report on Monday, July 27th.

Get Maplight Therapeutics alerts:

Read Our Latest Analysis on MPLT

Insider Buying and Selling at Maplight Therapeutics

In other Maplight Therapeutics news, Director Troy Cox purchased 15,620 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were acquired at an average price of $9.52 per share, for a total transaction of $148,702.40. Following the completion of the purchase, the director owned 15,620 shares in the company, valued at $148,702.40. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher A. Kroeger sold 118,235 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $27.19, for a total value of $3,214,809.65. Following the sale, the chief executive officer owned 1,394,094 shares of the company’s stock, valued at approximately $37,905,415.86. This trade represents a 7.82% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 275,013 shares of company stock valued at $7,696,771. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Maplight Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Strs Ohio bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $53,000. Blue Owl Capital Holdings LP acquired a new position in Maplight Therapeutics during the 4th quarter worth $5,745,000. Geode Capital Management LLC bought a new stake in shares of Maplight Therapeutics in the 4th quarter worth about $6,835,000. Seven Grand Managers LLC bought a new stake in shares of Maplight Therapeutics in the 4th quarter worth about $1,756,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $34,026,000.

Maplight Therapeutics Price Performance

Shares of NASDAQ MPLT opened at $12.55 on Thursday. Maplight Therapeutics has a 1-year low of $9.10 and a 1-year high of $40.43. The company has a market capitalization of $534.88 million and a price-to-earnings ratio of -0.31. The business has a 50-day moving average of $30.34 and a 200-day moving average of $24.88.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). Research analysts expect that Maplight Therapeutics will post -5.22 EPS for the current fiscal year.

Maplight Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

Featured Stories

• Five stocks we like better than Maplight Therapeutics
• SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
• Why Rare Earth Processing Could Be the Real 2027 Opportunity
• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
• TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.